Skip to main content
. Author manuscript; available in PMC: 2017 Jul 18.
Published in final edited form as: Cancer Immunol Immunother. 2011 Jan 26;60(5):629–638. doi: 10.1007/s00262-011-0970-1

Fig. 2.

Fig. 2

Chiral lipid interaction with BMDC. BMDC were treated with (R)-DOTAP or (S)-DOTAP liposomes (free of peptide) for 18 h and a dose-dependent activation of CD86 was evaluated (n = 3), as well as b dose-dependent CCL2 secretion after 24 h treatment (n = 3). c BMDCs were also evaluated for toxicity by PI staining of cells after 18 h treatment (one representative experiment shown, repeated in triplicate)